Working… Menu

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03761914
Recruitment Status : Recruiting
First Posted : December 3, 2018
Last Update Posted : March 17, 2021
Merck Sharp & Dohme Corp.
Cancer Insight, LLC
Information provided by (Responsible Party):
Sellas Life Sciences Group

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 31, 2024
Estimated Study Completion Date : April 30, 2024